Prothena Financial Statements From 2010 to 2026

PRTA Stock  USD 9.19  0.14  1.55%   
Prothena Plc's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Prothena Plc's valuation are provided below:
Prothena plc does not presently have any trending fundamental ratios for analysis.
Check Prothena Plc financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Prothena Plc's main balance sheet or income statement drivers, such as , as well as many indicators such as . Prothena financial statements analysis is a perfect complement when working with Prothena Plc Valuation or Volatility modules.
Check out the analysis of Prothena Plc Correlation against competitors.
For information on how to trade Prothena Stock refer to our How to Trade Prothena Stock guide.

Prothena plc Company Return On Equity Analysis

Prothena Plc's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Prothena Plc Return On Equity

    
  -0.68  
Most of Prothena Plc's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Prothena plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Prothena plc has a Return On Equity of -0.6763. This is 97.18% lower than that of the Biotechnology sector and 98.15% lower than that of the Health Care industry. The return on equity for all United States stocks is 118.16% higher than that of the company.

Prothena plc Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Prothena Plc's current stock value. Our valuation model uses many indicators to compare Prothena Plc value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Prothena Plc competition to find correlations between indicators driving Prothena Plc's intrinsic value. More Info.
Prothena plc is rated below average in return on equity category among its peers. It is regarded fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Prothena Plc's earnings, one of the primary drivers of an investment's value.

About Prothena Plc Financial Statements

Prothena Plc stakeholders use historical fundamental indicators, such as Prothena Plc's revenue or net income, to determine how well the company is positioned to perform in the future. Although Prothena Plc investors may analyze each financial statement separately, they are all interrelated. For example, changes in Prothena Plc's assets and liabilities are reflected in the revenues and expenses on Prothena Plc's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Prothena plc. Please read more on our technical analysis and fundamental analysis pages.
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company was founded in 2012 and is based in Dublin, Ireland. Prothena Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Prothena plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Prothena Plc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prothena Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prothena Plc Stock:
Check out the analysis of Prothena Plc Correlation against competitors.
For information on how to trade Prothena Stock refer to our How to Trade Prothena Stock guide.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prothena Plc. If investors know Prothena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prothena Plc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Prothena plc is measured differently than its book value, which is the value of Prothena that is recorded on the company's balance sheet. Investors also form their own opinion of Prothena Plc's value that differs from its market value or its book value, called intrinsic value, which is Prothena Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prothena Plc's market value can be influenced by many factors that don't directly affect Prothena Plc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prothena Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Prothena Plc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prothena Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.